Unbiased AI-powered news
2 stories related to this topic, newest first.
citizen.co.zaAllAfrica reported that GSK's Shingrix received SAHPRA registration in June 2026 and will launch at R2,783 per dose by the end of the month. Initial availability is limited to the private sector while public sector review remains pending.
sbs.com.auAhpra will use the definition in its regulatory work after a joint announcement with the federal antisemitism envoy. The move drew support from Jewish groups and criticism from a Palestinian advocacy network.